Target Validation Information
Target ID T47768
Target Name Mu-type opioid receptor
Target Type
Successful
Drug Potency against Target RTI-5989-31 Drug Info Ki = 3.1 nM [528947]
DIHYDROAKUAMMINE Drug Info IC50 = 6000 nM
M3B6S Drug Info Ki = 36.9 nM [551379]
Remifentanil Drug Info EC50 = 5.69 nM [553292]
DM6S Drug Info Ki = 1.5 nM [551379]
[Tyr-Pro-Phe-NH-CH2-]2 Drug Info IC50 = 218 nM [527490]
DPDPE Drug Info Ki = 2120 nM
1-benzhydryl-4-phenyl-4-propoxypiperidine Drug Info Ki = 1649 nM [528785]
1,6-bis-(Dmt-Tic-amino)hexane Drug Info IC50 = 2715 nM [527916]
H-D-Tic-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2 Drug Info IC50 = 1.2 nM [525699]
D-PhGly-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2 Drug Info IC50 = 350 nM [533376]
H-D-Trp-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2 Drug Info IC50 = 1.39 nM [525699]
D-Phe-Cys-Tyr--Trp-Lys-Thr-Pen-Thr-NH2 Drug Info IC50 = 1350 nM [533376]
1-benzhydryl-4-(4-chlorophenyl)piperidin-4-ol Drug Info Ki = 936 nM [528781]
5-(4-((phenethylamino)methyl)phenoxy)picolinamide Drug Info Ki = 1.77 nM [528996]
2-Benzylaminomethyl-3-hydroxymorphinan Drug Info Ki = 190 nM [530529]
1-benzhydryl-4-benzylpiperidin-4-ol Drug Info Ki = 10390 nM [528781]
H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-Bo Drug Info IC50 = 240 nM [528606]
MCL-145 Drug Info Ki = 0.2 nM [527951]
H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-O-Bzl Drug Info IC50 = 74 nM [529306]
6-(4-((phenethylamino)methyl)phenoxy)nicotinamide Drug Info Ki = 0.17 nM [529132]
17-Methylmorphinan-3-yl 4-Iodophenyl Carbamate Drug Info Ki = 0.34 nM [530529]
Ac-RYYRIK-K-(NH2)-YAFGYPS Drug Info IC50 = 0.15 nM [528282]
YRFB Drug Info IC50 = 1.18 nM [528282]
1-benzhydryl-4-methoxy-4-phenylpiperidine Drug Info Ki = 412 nM [528785]
1-benzhydryl-4-o-tolylpiperidin-4-ol Drug Info Ki = 74 nM [528781]
Tyr-D-Ala-Phe-Thr(-D-Glc)-Tyr-Pro-Ser-NH2 Drug Info Ki = 1700 nM [534460]
2-Hydroxymethyl-3-hydroxymorphinan Drug Info Ki = 15 nM [530529]
4-phenyl-1-(phenyl(p-tolyl)methyl)piperidin-4-ol Drug Info Ki = 3728 nM [528785]
6-(4-((benzylamino)methyl)phenoxy)nicotinamide Drug Info Ki = 4.09 nM [528996]
1-benzhydryl-4-(4-methoxyphenyl)piperidin-4-ol Drug Info Ki = 11050 nM [528781]
1-benzhydryl-4-tert-butylpiperidin-4-ol Drug Info Ki = 3599 nM [528781]
4-phenyl-1-(1-phenylethyl)piperidin-4-ol Drug Info Ki = 6265 nM [528785]
4-phenyl-1-(phenyl(m-tolyl)methyl)piperidin-4-ol Drug Info Ki = 147 nM [528785]
1-(2-ethoxy-1-phenylethyl)-4-phenylpiperidin-4-ol Drug Info Ki = 451 nM [528785]
4-phenyl-1-(1-phenylheptyl)piperidin-4-ol Drug Info Ki = 144 nM [528785]
4-phenyl-1-(1-phenylhexyl)piperidin-4-ol Drug Info Ki = 37 nM [528785]
1-benzhydryl-4-(3-phenylpropyl)piperidin-4-ol Drug Info Ki = 3364 nM [528781]
1-benzhydryl-4-(4-fluorophenyl)piperidin-4-ol Drug Info Ki = 771 nM [528781]
1-benzhydryl-4-(3-fluorophenyl)piperidin-4-ol Drug Info Ki = 705 nM [528781]
1-(dio-tolylmethyl)-4-phenylpiperidin-4-ol Drug Info Ki = 2147 nM [528785]
FALCARINDIOL Drug Info Ki = 1125 nM [529238]
H-Tyr-c[D-Orn-(D or L)Atc-Glu]-NH2 Drug Info Ki = 26.3 nM [528093]
H-Dmt-Tic-(2R,3S)-beta-MeCha-Phe-NH2 Drug Info Ki = 200 nM [528621]
H-Dmt-Tic-(2R,3R)-beta-MeCha-Phe-OH Drug Info Ki = 580 nM [528621]
HERKINORIN Drug Info Ki = 12 nM [529401]
14-O-phenylpropylnaltrexone Drug Info Ki = 0.34 nM [529991]
H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-3,5-Bzl(CF3)2 Drug Info IC50 = 52 nM [529306]
H-Dmt-Tic-Gly-NH-Bzl Drug Info Ki = 0.16 nM [529630]
Tyr-(S)-Aba-Gly-Phe-NH2 Drug Info Ki = 0.373 nM [529202]
H-Dmt-Tic-Glu-NH2 Drug Info Ki = 1360 nM [527332]
H-Dmt-Tic-Lys(Ac)-NH-CH2-Ph Drug Info Ki = 5.5 nM [528411]
[D-Ala2]Met-enkephalinamide Drug Info IC50 = 17.4 nM [533571]
N-alpha-amidino-Tyr(Me)-Pro-Trp-Phe-NH2 Drug Info IC50 = 988 nM [528594]
H-Dmt-Tic-NH-CH2-Imid Drug Info IC50 = 113.3 nM [529246]
CARBOXYFENTANYL Drug Info Ki = 5400 nM [529088]
SB-0304 Drug Info IC50 = 3640 nM [529395]
BREMAZOCINE Drug Info IC50 = 0.5 nM [531505]
H-Dmt-Tic-NH-CH2-Bta Drug Info IC50 = 129.1 nM [529246]
Dmt-Pro-Imp-Phe-NH2 Drug Info Ki = 0.32 nM [528832]
H-Dmt-Tic-Asp-NH-Bzl Drug Info Ki = 309.4 nM [529630]
H-Dmt-Tic-Asp-NH-Ph Drug Info Ki = 10.8 nM [529630]
MCL-433 Drug Info Ki = 1.4 nM [528655]
H-D-Phe-c[Cys-Tyr-DTrp-Orn-Thr-Pen]-Thr-NH2 Drug Info IC50 = 2.8 nM [529704]
MCL-432 Drug Info Ki = 3.7 nM [528655]
MCL-428 Drug Info IC50 = 22 nM [528655]
MCL-431 Drug Info Ki = 4.8 nM [528655]
DELTORPHIN-II Drug Info Ki = 638 nM [531038]
MCL-434 Drug Info Ki = 5.3 nM [528655]
MCL-147 Drug Info Ki = 1.5 nM [528787]
MCL-445 Drug Info Ki = 22 nM [528787]
MCL-183 Drug Info Ki = 7.1 nM [528787]
MCL-182 Drug Info Ki = 3.7 nM [528787]
H-Dmt-Tic-Lys-NH-CH2-Ph Drug Info Ki = 4.05 nM [528411]
MR-2034 Drug Info Ki = 0.19 nM [529816]
SOMATOSTATIN Drug Info IC50 = 6 nM [533376]
H-2',6'-dimethyltyrosine-Tic-OH Drug Info Ki = 1360 nM [530447]
H-Dmt-Aba-Gly-NH-Ph Drug Info IC50 = 95 nM [528269]
8-azabicyclo[3.2.1]octan-3-yloxy-benzamide Drug Info IC50 = 721 nM [531109]
MM3A6S Drug Info Ki = 34.2 nM [551379]
Tyr-Pro-Dmt-Phe-NH2 Drug Info Ki = 2.63 nM [528832]
H-Dmt-Tic-Gly-NH-Ph Drug Info Ki = 0.16 nM [529630]
H-Dmt-Tic-NH-(R)CH(CH2-COOH)-Bid(N1-Me) Drug Info Ki = 11.8 nM [529630]
Dmt-Pro-Mmp-Phe-NH2 Drug Info Ki = 0.18 nM [528832]
H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-NH2 Drug Info Ki = 330 nM [528621]
Tyr-Pro-Phe-Phe-NHNH2 Drug Info Ki = 9.35 nM [529480]
Naltrexone-6-alpha-ol Drug Info Ki = 0.21 nM [529816]
H-Dmt-Tic-NH-CH2-ImidPh Drug Info IC50 = 153.5 nM [529246]
H-Dmt-Tic-Asp-N(Me)-Ph Drug Info Ki = 364.3 nM [529630]
Tyr-Pro-D-Phe-Pro-NH2 Drug Info IC50 = 109 nM [534004]
6-desoxonaltrexone Drug Info IC50 = 4.4 nM [530013]
[Dcp1]Dyn A(1-11)-NH2 Drug Info Ki = 44.9 nM [528376]
H-Dmt-Tic-NH-CH[(CH2)4-NH-Ac]-Bid Drug Info IC50 = 53.9 nM [528411]
MCL-451 Drug Info Ki = 1100 nM [528412]
Tyr-(R)-Aba-Gly-Phe-NH2 Drug Info Ki = 2.245 nM [529202]
Tyr-Pro-L-Phe-Pro-NH2 Drug Info IC50 = 552 nM [534004]
Dmt-Pro-Phe-D-2-Nal-NH2 Drug Info Ki = 1.52 nM [528646]
Tyr-Pro-Phe-Hfe-NH2 Drug Info Ki = 74.5 nM [528190]
Tyr-Pro-Phe-Phe-NHCH3 Drug Info Ki = 29.17 nM [529480]
H-Apa-ala-Gly-Phe-leu-OH Drug Info Ki = 1400 nM [528724]
H-Aba-ala-Gly-Phe-Met-OH Drug Info Ki = 100 nM [528724]
H-mCpa-ser-Gly-Phe-Leu-Thr-OH Drug Info Ki = 1100 nM [528724]
H-mCpa-ala-Gly-Phe-leu-OH Drug Info Ki = 560 nM [528724]
H-Dmt-Tic-Lys(Z)-NH-Ph Drug Info IC50 = 438 nM [528411]
C[L-Phe-D-pro-L-Phe-L-trp] Drug Info IC50 = 260 nM [530160]
H-Dmt-Tic-Glu-NH-(CH2)5-NH2 Drug Info Ki = 380 nM [527332]
C[L-Ala-D-pro-L-Phe-D-trp] Drug Info IC50 = 48 nM [530160]
Tyr-Pro-L-(NMe)Phe-D-Pro-NH2 Drug Info IC50 = 20.7 nM [534004]
H-Dmt-Tic-NH-(CH2)6-NH-Dmt-H Drug Info IC50 = 5900 nM [527758]
H-Tyr-Gly-Gly-Phe-Met-NH2 Drug Info Ki = 12 nM [528724]
Tyr-Pro-L-(NMe)Phe-Pro-NH2 Drug Info IC50 = 170 nM [534004]
3,6-bis(Dmt-Tic-NH-methyl)-2(1H)-pyrazinone Drug Info Ki = 3.76 nM [527916]
H-Cdp-ser-Gly-Phe-Leu-Thr-OH Drug Info Ki = 19 nM [528724]
H-Tyr-Pro-Phe-Phe-NH-(CH2)5-(C=O)-Dap(6DMN)-NH2 Drug Info IC50 = 253 nM [528238]
Tyr-(S)-spiro-Aba-Gly-Phe-NH2 Drug Info Ki = 8.732 nM [529202]
1,10-bis-(Dmt-Tic-amino)decane Drug Info IC50 = 5425 nM [527916]
H-Dmt-Tic-Lys(Ac)-NH-Ph Drug Info IC50 = 1248 nM [528411]
H-2',6'-dimethyltyrosine-Tic-Phe-Phe-OH Drug Info IC50 = 769 nM [530447]
CCDC 710249, HCl salt Drug Info IC50 = 0.88 nM [530013]
H-Dmt-Tic-NH-CH[(CH2)4-NH2]-Bid Drug Info IC50 = 39.7 nM [528411]
Tyr-D-Phe-Gly-Trp-NMeNle-Asp-Phe-NH2 Drug Info IC50 = 100 nM [528193]
H-Dmt-Tic-NH-(D)-CH[(CH2)4-NH-Z]-Bid Drug Info IC50 = 62.5 nM [528411]
1-benzhydryl-4-cyclopropylpiperidin-4-ol Drug Info Ki = 18365 nM [528781]
Tyr-D-Nle-Gly-D-Trp-Nle-Asp-Phe-NH2 Drug Info IC50 = 1000 nM [528193]
H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-OH Drug Info Ki = 280 nM [528621]
H-Dmt-Tic-(2R,3S)-beta-MeCha-Phe-OH Drug Info Ki = 55 nM [528621]
Tyr-D-Ala-Gly-D-Trp-Nle-Asp-Phe-NH2 Drug Info IC50 = 2300 nM [528193]
1-benzhydryl-4-(thiophen-2-yl)piperidin-4-ol Drug Info Ki = 1734 nM [528781]
H-Dmt-Tic-(2R,3R)-beta-MeCha-Phe-NH2 Drug Info Ki = 290 nM [528621]
H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-OH Drug Info Ki = 1400 nM [528621]
H-Tyr-Tic-Cha-Phe-OH Drug Info Ki = 3600 nM [528621]
H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-Bzl Drug Info IC50 = 9 nM [529306]
H-Dmt-Tic-D-Asp-NH-Ph Drug Info Ki = 7.49 nM [529630]
1-benzhydryl-4-butylpiperidin-4-ol Drug Info Ki = 272 nM [528781]
N-alpha-amidino-Tyr(Me)-D-Pro-Gly-Trp-Phe-NH2 Drug Info Ki = 1062 nM [528594]
H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-Bzl Drug Info IC50 = 13 nM [529306]
4-phenyl-1-(1-phenylpentyl)piperidin-4-ol Drug Info Ki = 29 nM [528785]
1-benzhydryl-4-isopropylpiperidin-4-ol Drug Info Ki = 13230 nM [528781]
H-Tyr-c[D-Cys-Gly-Phe-D-Cys]NH2 Drug Info Ki = 0.55 nM [528692]
N-(17-Methylmorphinan-3-yl)-N'-phenylurea Drug Info Ki = 11 nM [530529]
1-(1,2-diphenylethyl)-4-phenylpiperidin-4-ol Drug Info Ki = 24 nM [528785]
H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]-OH Drug Info IC50 = 59 nM [528875]
MCL-154 Drug Info Ki = 66 nM [530707]
Tyr-D-Ala-Gly-Trp-Nle-Asp-Phe-NH2 Drug Info IC50 = 160 nM [528193]
Tyr-D-Pro-Gly-Trp-NMeNle-Asp-Phe-NH2 Drug Info Ki = 2600 nM [528193]
Tyr-D-Phe-Gly-D-Trp-Nle-Asp-Phe-NH2 Drug Info IC50 = 2700 nM [528193]
Tyr-Gly-Gly-Trp-NMeNle-Asp-Phe-NH2 Drug Info IC50 = 4200 nM [528193]
SNF-9007 Drug Info IC50 = 220 nM [528193]
Tyr-D-Phe-Gly-Trp-Nle-Asp-Phe-NH2 Drug Info IC50 = 420 nM [528193]
Tyr-D-Phe-Gly-D-Trp-NMeNle-Asp-Phe-NH2 Drug Info IC50 = 71 nM [528193]
H-Tyr-D-Ala-Gly-Phe-NH-NH-(NMe)Phe-Asp-Nle-Trp-Ac Drug Info IC50 = 62 nM [528058]
H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-Boc Drug Info IC50 = 460 nM [528058]
C[L-Phe-D-pro-L-Tyr(OMe)-D-trp] Drug Info Ki = 43 nM [530160]
1-benzhydryl-4-p-tolylpiperidin-4-ol Drug Info Ki = 940 nM [528781]
1-benzhydryl-4-phenylpiperidin-4-ol Drug Info Ki = 233 nM [530052]
1-benzhydryl-4-(4-bromophenyl)piperidin-4-ol Drug Info Ki = 1057 nM [528781]
N-Benzyl-17-(cyclobutylmethyl)morphinan-3-amine Drug Info Ki = 1.7 nM [530529]
4-phenyl-1-(1-phenylbutyl)piperidin-4-ol Drug Info Ki = 341 nM [528785]
H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]NH2 Drug Info Ki = 1.17 nM [528692]
N-Benzyl-17-(cyclopropylmethyl)morphinan-3-amine Drug Info Ki = 0.26 nM [530529]
H-Tyr-c[D-Cys-Gly-Phe-L-Cys]NH2 Drug Info Ki = 1.74 nM [528692]
Trans-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH Drug Info IC50 = 5.2 nM [528875]
MCL-448 Drug Info IC50 = 380 nM [528787]
1-benzhydryl-4-hexylpiperidin-4-ol Drug Info Ki = 8899 nM [528781]
1-benzhydryl-4-m-tolylpiperidin-4-ol Drug Info Ki = 273 nM [528781]
6-(4-(2-(benzylamino)ethyl)phenoxy)picolinamide Drug Info Ki = 643.47 nM [528996]
1-benzhydryl-4-(furan-2-yl)piperidin-4-ol Drug Info Ki = 4554 nM [528781]
6-(2-benzylisoindolin-5-yloxy)nicotinamide Drug Info Ki = 1008 nM [529132]
N-(4-Iodophenyl)-N'-(17-methylmorphinan-3-yl)urea Drug Info Ki = 17 nM [530529]
M3Pr6S Drug Info Ki = 0.6 nM [551379]
Tyr-D-Ala-Gly-Phe-Met-Pro-Leu-Trp-NH-Bzl Drug Info IC50 = 61 nM [529724]
C[L-Tyr(OMe)-D-pro-L-Phe-D-trp] Drug Info Ki = 170 nM [530160]
C[L-Phe-D-pro-L-mTyr-D-trp] Drug Info Ki = 40 nM [530160]
[Tyr-Pro-Phe-NH-]2 Drug Info IC50 = 1135 nM [527490]
H-Tyr-c[D-Orn-Aic-Glu]-NH2 Drug Info Ki = 4.21 nM [528093]
MCL-429 Drug Info IC50 = 6.4 nM [528655]
6-(2-phenethylisoindolin-5-yloxy)nicotinamide Drug Info Ki = 658.8 nM [529132]
6-(4-(2-(benzylamino)ethyl)phenoxy)nicotinamide Drug Info Ki = 7.44 nM [529132]
H-Tyr-D-Ala-(R or S)Atc-Asp-Val-Val-Gly-NH2 Drug Info IC50 = 0.38 nM [533958]
(-)-eseroline Drug Info IC50 = 300 nM
LOFENTANIL Drug Info IC50 = 0.25 nM [533543]
NORBINALTORPHIMINE Drug Info Ki = 28.2 nM [531086]
H-Tyr-Pro-Dap(6DMN)-Phe-NH2 Drug Info IC50 = 389 nM [528238]
4-(Spiro[chromene-2,4'-piperidine]-4-yl)benzamide Drug Info Ki = 2700 nM [530324]
8-carboxamidocyclazocine Drug Info Ki = 0.31 nM [529429]
SN-23 Drug Info Ki = 23.61 nM [530073]
MM3B6S Drug Info Ki = 444 nM [551379]
SB-213698 Drug Info Ki = 284.14 nM [530073]
U-69593 Drug Info Ki = 692 nM [551379]
M6S Drug Info Ki = 0.9 nM [551379]
M3P6S Drug Info Ki = 0.7 nM [551379]
KNT-62 Drug Info Ki = 0.205 nM [530556]
DC6S Drug Info Ki = 196 nM [551379]
MCL-443 Drug Info IC50 = 260 nM [528655]
MCL-449 Drug Info IC50 = 10 nM [528655]
DM3B6S Drug Info Ki = 61.8 nM [551379]
MR-1029 Drug Info IC50 = 6.8 nM [528070]
MCL-458 Drug Info Ki = 5.8 nM [528787]
HTyr-Gly-Gly-Phe-Leu-Arg-Arg-lle-Arg-Pro-LysNH2 Drug Info Ki = 1.85 nM [530428]
CODEINONE Drug Info Ki = 459 nM [528939]
THEBAINE Drug Info Ki = 7400 nM [528939]
ORIPAVINE Drug Info Ki = 286 nM [528939]
Dynorphin(1-8) Drug Info Ki = 340 nM [533377]
MCL-153 Drug Info Ki = 29 nM [530707]
Dmt-Pro-Phe-Phe-NH2 Drug Info Ki = 0.26 nM [528832]
Tyr-Pro-Mmp-Phe-NH Drug Info Ki = 0.22 nM [528832]
Dhp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2 Drug Info Ki = 4.79 nM [528376]
3-desoxy-3-carboxamidonaltrexone Drug Info IC50 = 270 nM [530013]
Deprotected cogener of M6G Drug Info Ki = 3.5 nM [527461]
H-Cpa-Gly-Gly-Phe-Met-OH Drug Info Ki = 28 nM [528724]
H-Cdp-ala-Gly-Phe-leu-OH Drug Info Ki = 9.8 nM [528724]
Oxymorphone semicarbazone hydrochloride Drug Info Ki = 14.5 nM [533377]
C[L-Phe-D-pro-L-Phe-D-trp] Drug Info IC50 = 21 nM [530160]
C[L-Phe-D-pro-L-Tyr-D-trp] Drug Info Ki = 120 nM [530160]
Clocinnamox Drug Info Ki = 3 nM [529991]
H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-H Drug Info IC50 = 81 nM [528058]
1-benzhydryl-4-cyclohexylpiperidin-4-ol Drug Info Ki = 407 nM [528781]
1-benzhydryl-4-(2-methoxyphenyl)piperidin-4-ol Drug Info Ki = 983 nM [528781]
H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Phe-D-Asp-D-Nle-Trp-H Drug Info IC50 = 97 nM [528606]
1-benzhydryl-4-(4-propylphenyl)piperidin-4-ol Drug Info Ki = 11430 nM [528781]
Cis-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH Drug Info IC50 = 5.3 nM [528875]
Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-NMeNle-D-Trp-Boc Drug Info Ki = 20 nM [528058]
H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-3,5-Bzl(CF3)2 Drug Info IC50 = 350 nM [529306]
H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-H Drug Info IC50 = 93 nM [528606]
H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Boc Drug Info IC50 = 55 nM [528058]
17-(Cyclobutylmethyl)-N-phenylmorphinan-3-amine Drug Info Ki = 1.7 nM [530529]
Tyr-Pro-L-Phe-D-Pro-NH2 Drug Info IC50 = 28.7 nM [534004]
H-Dmt-Tic-Glu-Dap(6DMN)-NH(2) Drug Info IC50 = 100 nM [528238]
N-isobutylnoroxymorphone Drug Info Ki = 5.57 nM [529662]
AMINOFENTANYL Drug Info IC50 = 2080 nM [528300]
Tyr-Pro-D-(NMe)Phe-D-Pro-NH2 Drug Info IC50 = 2660 nM [534004]
Tyr-D-Ala-Phe-Asp-Val-Val-Thr[Beta-D-Glc]-Gly-NH2 Drug Info Ki = 578.9 nM [534460]
FLUPERAMIDE Drug Info Ki = 0.11 nM [527228]
DAMGO Drug Info Ki = 0.87 nM
H-Tyr-D-Ala-Gly-Phe-D-Leu Drug Info IC50 = 24 nM [528853]
GBR-12909 Drug Info IC50 = 3530 nM [526156]
Tyr-D-Ala-Gly-Phe-Met-NH2 Drug Info Ki = 0.5 nM [531023]
6beta-naltrexol HCl Drug Info Ki = 2.12 nM [530077]
H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-NH2 Drug Info IC50 = 0.509 nM [527693]
H-Tyr-D-Ala-Aic-Asp-Val-Val-Gly-NH2 Drug Info IC50 = 0.41 nM [533958]
Antanal 1 Drug Info Ki = 2.38 nM [529704]
H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Ac Drug Info IC50 = 28 nM [528058]
C6S Drug Info Ki = 38.7 nM [551379]
M3S Drug Info Ki = 101 nM [551379]
NalBzOH Drug Info Ki = 0.2 nM [551379]
SN-11 Drug Info Ki = 0.77 nM [530073]
M3A6S Drug Info Ki = 0.8 nM [551379]
M3IBu6S Drug Info Ki = 19.8 nM [551379]
MCL-149 Drug Info Ki = 1.3 nM [528787]
MCL-444 Drug Info IC50 = 16 nM [528655]
MCL-435 Drug Info Ki = 1.2 nM [528655]
MCL-457 Drug Info Ki = 160 nM [528787]
DM3A6S Drug Info Ki = 13.7 nM [551379]
KNT-63 Drug Info Ki = 0.212 nM [530556]
6-(Allyl-methyl-amino)-4,4-diphenyl-heptan-3-ol Drug Info Ki = 150 nM [533539]
Dimepheptanol Drug Info Ki = 230 nM [533539]
TRK-820 Drug Info Ki = 0.582 nM [530556]
MCL-447 Drug Info IC50 = 1500 nM [528787]
MCL-446 Drug Info Ki = 12 nM [528787]
UFP-502 Drug Info IC50 = 26.92 nM [531038]
YPAA-NH2 Drug Info Ki = 705 nM [529365]
YGWFL-NH2 Drug Info IC50 = 132.4 nM [529365]
MORPHINONE Drug Info Ki = 146 nM [528939]
YGGWL-NH2 Drug Info IC50 = 49.2 nM [529365]
SALVINORIN A Drug Info Ki = 4370 nM [529401]
H-Tyr-Pro-Ala-Phe-NH2 Drug Info Ki = 225.9 nM [529365]
Bis-((-)-N-propargylmorphinan-3-yl) sebacoylate Drug Info Ki = 14 nM [527951]
Tyr-D-Ala-Phe-Thr[-D-Glc(OAc)4]-Tyr-Pro-Ser-NH2 Drug Info Ki = 4400 nM [534460]
Tyr-Pro-Trp-D-Ala-Bn Drug Info Ki = 4.56 nM [530314]
Dmt-Pro-Emp-Phe-NH2 Drug Info Ki = 0.21 nM [528832]
Tyr-Pro-3,5Dmp-Phe-NH2 Drug Info Ki = 6.19 nM [528832]
Tyr-Pro-D-Phg-Phe-NH2 Drug Info Ki = 1347 nM [528190]
Dmt-Pro-3,5Dmp-Phe-NH2 Drug Info Ki = 0.11 nM [528832]
Tyr-Pro-Imp-Phe-NH2 Drug Info Ki = 0.45 nM [528832]
Tyr-Pro-Phe-D-Phg-NH2 Drug Info Ki = 216 nM [528190]
H-Dmt-Aba-Gly-NH-CH2-Bid Drug Info IC50 = 231 nM [528269]
Tyr-Pro-Hfe-Pro-NH2 Drug Info Ki = 586 nM [528190]
Tyr-Pro-Emp-Phe-NH2 Drug Info Ki = 0.46 nM [528832]
Tyr-Pro-Phg-Pro-NH2 Drug Info Ki = 1042 nM [528190]
Dmt-Pro-Tmp-Phe-NH2 Drug Info Ki = 0.18 nM [528832]
Tyr-Pro-Trp-D-Val-Bn Drug Info Ki = 2.32 nM [530314]
KETOCYCLAZOCINE Drug Info Ki = 3.3 nM [529816]
H-Dmt-Tic-Gly-N(Me)-Ph Drug Info Ki = 1.75 nM [529630]
Tyr-Pro-Phe-Phe-OC(CH3)3 Drug Info Ki = 50.35 nM [529480]
Tyr-Pro-Trp-Gly-Bn Drug Info Ki = 56.23 nM [530314]
H-Dmt-Tic-NH-CH2-Indn Drug Info IC50 = 28.41 nM [529246]
H-Dmt-Tic-NH-CH2-Indl Drug Info IC50 = 208.9 nM [529246]
H-Dmt-Tic-D-Asp-N(Me)-Ph Drug Info Ki = 45 nM [529630]
Tyr-Pro-Phe-Phe-OCH2OH Drug Info Ki = 6.34 nM [529480]
O-DESMETHYL TRAMADOL Drug Info Ki = 8.6 nM [529816]
Tyr-Pro-Phe-Phe-OCH3 Drug Info Ki = 9.07 nM [529480]
Tyr-Pro-Phg-Phe-NH2 Drug Info Ki = 268 nM [528190]
H-Dmt-Tic-NH-CH2-Boa Drug Info IC50 = 169.9 nM [529246]
MCL-450 Drug Info IC50 = 97 nM [528412]
Tyr-Pro-Phe-Phe-N(CH3)2 Drug Info Ki = 272.7 nM [529480]
Tyr-Pro-Tmp-Phe-NH Drug Info Ki = 0.44 nM [528832]
DERMORPHIN Drug Info IC50 = 0.538 nM [528282]
KNT-5 Drug Info Ki = 24 nM [530626]
H-Dmt-Tic-Lys-NH-Ph Drug Info IC50 = 1254 nM [528411]
Tyr-D-Ala-Gly-NMePhe Drug Info IC50 = 1000 nM [530269]
Tyr-(R)-spiro-Aba-Gly-Phe-NH2 Drug Info IC50 = 49.81 nM [529202]
H-Dmt-Tic-Gly-NH-CH2-Bid Drug Info IC50 = 26.9 nM [528269]
H-Dmt-Tic-Lys(Z)-NH-CH2-Ph Drug Info Ki = 4.41 nM [528411]
Tyr-(NMe)Ala-L-Phe-D-Pro-NH2 Drug Info IC50 = 30.6 nM [534004]
H-Tyr-Gly-Gly-Phe-Met-OH Drug Info Ki = 19 nM [528724]
H-Dmt-Tic-NH-(S)CH(CH2-COOH)-Bid(N1-Me) Drug Info Ki = 5.93 nM [529630]
H-Aba-ala-Gly-Phe-leu-OH Drug Info Ki = 1200 nM [528724]
H-Aba-ser-Gly-Phe-Leu-Thr-OH Drug Info Ki = 640 nM [528724]
Tyr-Pro-Phe-Phe-OCH2CH3 Drug Info Ki = 14.96 nM [529480]
H-Tyr-Pro-Phe-Phe-NH-CH2-CH2-NH Tic Dmt-H Drug Info IC50 = 25.1 nM [529041]
Leucine-enkephalin Drug Info Ki = 380 nM [533377]
H-Aba-Gly-Gly-Phe-Leu-OH Drug Info Ki = 1200 nM [528724]
Ac-L-Phe-D-trp-L-Phe-D-pro-NH2 Drug Info Ki = 360 nM [530160]
[Tyr-Pro-Phe-Phe-NH-]2 Drug Info IC50 = 518 nM [527490]
Ac-D-pro-L-Phe-D-trp-L-Phe-NH2 Drug Info Ki = 340 nM [530160]
(H-Dmt-Tic-Glu-NH-(CH(2))(5)-CO-Dap(6DMN)-NH(2) Drug Info IC50 = 244 nM [528238]
H-Dmt-Tic-NH-(CH2)6-NH-Phe-H Drug Info IC50 = 5550 nM [527758]
Tyr-Pro-D-Phe-D-Pro-NH2 Drug Info IC50 = 557 nM [534004]
H-Cdp-Gly-Gly-Phe-Leu-OH Drug Info Ki = 9.8 nM [528724]
3,6-bis(Dmt-Tic-NH-butyl)-2(1H)-pyrazinone Drug Info Ki = 1.74 nM [527916]
H-Cpa-Gly-Gly-Phe-Met-NH2 Drug Info Ki = 18 nM [528724]
C[L-mTyr-D-pro-L-Phe-D-trp] Drug Info Ki = 37 nM [530160]
H-Dmt-Tic-NH-CH[(CH2)4-NH-Z]-Bid Drug Info IC50 = 375 nM [528411]
Tyr-D-Ala-Gly-Trp-NMeNle-Asp-Phe-NH2 Drug Info IC50 = 470 nM [528193]
4-phenyl-1-(1-phenylpropyl)piperidin-4-ol Drug Info Ki = 2298 nM [528785]
Tyr-D-Nle-Gly-Trp-NMeNle-Asp-Phe-NH2 Drug Info IC50 = 48 nM [528193]
H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-NH2 Drug Info Ki = 170 nM [528621]
Dcp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2 Drug Info Ki = 2.84 nM [528376]
Tyr-D-Ala-Gly-D-Trp-NMeNle-Asp-Phe-NH2 Drug Info IC50 = 150 nM [528193]
Tyr-Pro-Phe-D-Val-Bn Drug Info Ki = 4.97 nM [530314]
Alvimopan Drug Info Ki = 0.44 nM
Tyr-D-Nle-Gly-Trp-Nle-Asp-Phe-NH2 Drug Info IC50 = 210 nM [528193]
1-benzhydryl-4-(3-methoxyphenyl)piperidin-4-ol Drug Info Ki = 2988 nM [528781]
3,6-bis(Dmt-Tic-NH-ethyl)-2(1H)-pyrazinone Drug Info Ki = 2.83 nM [527916]
H-Dmt-Tic-NH-(R)CH(CH2-COOH)-Bid Drug Info Ki = 16.1 nM [529630]
1-benzhydryl-4-(pyridin-2-yl)piperidin-4-ol Drug Info Ki = 11540 nM [528781]
1-benzhydryl-4-ethoxy-4-phenylpiperidine Drug Info Ki = 377 nM [528785]
1-benzhydryl-4-(2-fluorophenyl)piperidin-4-ol Drug Info Ki = 589 nM [528781]
D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2(CTP) Drug Info IC50 = 3.7 nM [533376]
3,6-bis(Dmt-Tic-NH-propyl)-2(1H)-pyrazinone Drug Info IC50 = 7025 nM [527916]
1-benzhydryl-4-(4-ethylphenyl)piperidin-4-ol Drug Info Ki = 3433 nM [528781]
1,4-bis-(Dmt-Tic-amino)butane Drug Info Ki = 5.72 nM [527916]
H-D-Tca-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2 Drug Info IC50 = 173 nM [525699]
LY-255582 Drug Info Ki = 0.15 nM [529132]
Tyr-Pro-Phe-D-2-Nal-NH2 Drug Info IC50 = 19.5 nM [529264]
(+/-)-nantenine Drug Info Ki = 7265 nM [530558]
MC-CAM Drug Info Ki = 4.78 nM [530461]
BUTORPHAN Drug Info Ki = 0.12 nM [525672]
SL-3111 Drug Info IC50 = 17000 nM [525682]
METAZOCINE Drug Info IC50 = 94 nM [533571]
Antanal 2 Drug Info Ki = 1.52 nM [529704]
H-Dmt-Tic-NH-(CH2)6-NH-Tic-H Drug Info IC50 = 1600 nM [527758]
OXYMORPHINDOLE Drug Info Ki = 66 nM [529414]
MR-2266 Drug Info IC50 = 2.9 nM [528070]
H-Tyr-D-Ala-Tic-Asp-Val-Val-Gly-NH2 Drug Info IC50 = 156 nM [533958]
2-(2-methylquinolin-4-ylamino)-N-phenylacetamide Drug Info IC50 = 1.15 nM [530283]
Ac-YGGFL-NH2 Drug Info Ki = 37.3 nM [529365]
YPWA-NH2 Drug Info Ki = 72.7 nM [529365]
YAWF-NH2 Drug Info Ki = 3190 nM [529365]
BIPHALIN Drug Info Ki = 1.4 nM [531023]
Ac-RYYRIK-K-(NH2)-YRFB Drug Info IC50 = 2.76 nM [528282]
PHENAZOCINE Drug Info Ki = 0.2 nM [529816]
Tyr-Sar-Phe-D-2-Nal-NH2 Drug Info IC50 = 1560 nM [529264]
SN-28 Drug Info Ki = 10.8 nM [531165]
4-(4-((phenethylamino)methyl)phenoxy)benzamide Drug Info Ki = 0.29 nM [528996]
UFP-512 Drug Info IC50 = 1724 nM [531038]
MCL-144 Drug Info IC50 = 16 nM [530279]
H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-OH Drug Info IC50 = 63 nM [527693]
Tyr-D-Ala-Phe-Gly-Tyr-Pro-Thr(Beta-D-Glc)-Gly-NH2 Drug Info Ki = 0.29 nM [534460]
Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2 Drug Info IC50 = 3180 nM [533971]
Tyr-D-Met-Phe-His-Leu-Met-Asp-NH2 Drug Info IC50 = 3400 nM [533971]
3-(1-benzylpiperidin-4-yl)-5-chloro-1H-indole Drug Info Ki = 230 nM [528151]
H-Dmt-Aba-Gly-NH-CH2-Ph Drug Info IC50 = 51 nM [528269]
NOCICEPTIN Drug Info Ki = 3030 nM [529276]
N-alpha-amidino-Tyr(Me)-Pro-Trp-p-Cl-Phe-NH2 Drug Info IC50 = 845 nM [528594]
Tyr-Pro-Phe-Ala-Bn Drug Info Ki = 122 nM [530314]
SPIROINDANYLOXYMORPHONE Drug Info Ki = 10.6 nM [530268]
DELTORPHIN Drug Info IC50 = 910 nM [529509]
Benzyl derivative of M6G Drug Info Ki = 0.5 nM [527461]
C[L-Tyr-D-pro-L-Phe-D-trp] Drug Info Ki = 670 nM [530160]
ENDOMORPHIN-1 Drug Info Ki = 10.7 nM [530234]
Tyr-Pro-Phe-Phg-NH2 Drug Info Ki = 26.9 nM [528190]
MR-1526 Drug Info IC50 = 84 nM [528070]
D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2(CTAP) Drug Info IC50 = 3.5 nM [533376]
ELAEOCARPENINE Drug Info Ki = 18000 nM [530705]
MORPHICEPTIN Drug Info Ki = 135 nM [531092]
Tyr-D-Nle-Gly-D-Trp-NMeNle-Asp-Phe-NH2 Drug Info Ki = 1200 nM [528193]
Beta-funaltrexamine Drug Info IC50 = 2.2 nM [530269]
Dmt-Pro-Trp-D-2-Nal-NH2 Drug Info Ki = 2.38 nM [528646]
Dmt-Pro-Phe-D-1-Nal-NH2 Drug Info Ki = 1.24 nM [528646]
6-(4-(3-(benzylamino)propyl)phenoxy)nicotinamide Drug Info Ki = 22.26 nM [528996]
1,6-bis-(N,N-dimethyl-Dmt-Tic-NH)hexane Drug Info Ki = 2.21 nM [527916]
H-Dmt-Tic-OH Drug Info Ki = 3320 nM [527916]
Tyr-Pro-Hfe-Phe-NH2 Drug Info Ki = 28.4 nM [528190]
Tyr-Pro-Phe-D-Ala-Bn Drug Info Ki = 8.67 nM [530314]
[Tyr-Pro-Phe-Phe-NH-CH2-]2 Drug Info IC50 = 3544 nM [527490]
AKUAMMINE Drug Info IC50 = 3000 nM
3-(2-Methyl-2-aza-bicyclo[3.3.1]non-5-yl)-phenol Drug Info Ki = 63 nM [526733]
CYPRODIME Drug Info Ki = 10600 nM [527092]
GUANIDINONALTRINDOLE Drug Info Ki = 36.9 nM [526656]
Naloxone Drug Info IC50 = 7.6 nM [553157]
ZYKLOPHIN Drug Info Ki = 5880 nM [530428]
17-methyl-4'-methyldihydromorphinone Drug Info Ki = 0.34 nM [528375]
Naltrexone-6-beta-ol Drug Info Ki = 0.19 nM [529816]
H-Dmt-Tic-NH-CH2-CH2-NH2 Drug Info IC50 = 285.6 nM [529041]
(+/-)-TRANS-U-50488 METHANESULFONATE Drug Info IC50 = 1 nM
H-Tyr-D-Ala-Gly Phe-Pro-Leu-Trp-O-3,5-Bzl(CF3)2 Drug Info IC50 = 520 nM [529306]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one Drug Info Ki < 1000 nM [531079]
Opioid Peptide [d-Ala(8)]Dynorphin derivative Drug Info Ki = 1.03 nM [526710]
(-)-cyclorphan Drug Info IC50 = 1.7 nM [527951]
MCL-139 Drug Info Ki = 0.16 nM [527951]
H-Tyr-D-Ala-Gly-Phe-NH-NH-Trp-D-Nle-D-Asp-D-Phe-H Drug Info IC50 = 76 nM [528606]
[Leu5]enkephalin Drug Info Ki = 9.43 nM [530780]
ENDOMORPHIN 2 Drug Info IC50 = 15 nM [531092]
Action against Disease Model Buprenorphine For MOR/CHO cell line Ki: 12.4 nM [552429] Drug Info
References
Ref 528947J Med Chem. 2007 Aug 9;50(16):3765-76. Epub 2007 Jul 11.Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series.
Ref 551379Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. Epub 2006 Jun 13.
Ref 553292The comparative pharmacodynamics of remifentanil and its metabolite, GR90291, in a rat electroencephalographic model. Anesthesiology. 1999 Feb;90(2):535-44.
Ref 551379Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. Epub 2006 Jun 13.
Ref 527490Bioorg Med Chem Lett. 2005 Apr 1;15(7):1847-50.Structure-activity relationship of the novel bivalent and C-terminal modified analogues of endomorphin-2.
Ref 528785Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
Ref 527916J Med Chem. 2005 Dec 15;48(25):8035-44.Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists.
Ref 525699J Med Chem. 2000 Feb 24;43(4):569-80.Opiate aromatic pharmacophore structure-activity relationships in CTAP analogues determined by topographical bias, two-dimensional NMR, and biological activity assays.
Ref 533376J Med Chem. 1986 Nov;29(11):2370-5.Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors.
Ref 525699J Med Chem. 2000 Feb 24;43(4):569-80.Opiate aromatic pharmacophore structure-activity relationships in CTAP analogues determined by topographical bias, two-dimensional NMR, and biological activity assays.
Ref 533376J Med Chem. 1986 Nov;29(11):2370-5.Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 528996Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52. Epub 2007 Aug 11.Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1.
Ref 530529J Med Chem. 2010 Jan 14;53(1):402-18.Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 528606J Med Chem. 2007 Jan 11;50(1):165-8.Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors.
Ref 527951J Med Chem. 2006 Jan 12;49(1):256-62.Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors.
Ref 529306J Med Chem. 2008 Mar 13;51(5):1369-76. Epub 2008 Feb 12.A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists.
Ref 529132Bioorg Med Chem Lett. 2007 Dec 15;17(24):6841-6. Epub 2007 Oct 17.Structure activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 2.
Ref 530529J Med Chem. 2010 Jan 14;53(1):402-18.Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors.
Ref 528282Bioorg Med Chem Lett. 2006 Sep 15;16(18):4839-41. Epub 2006 Jun 30.Synthesis and receptor binding properties of chimeric peptides containing a mu-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac-RYYRIK-amide.
Ref 528282Bioorg Med Chem Lett. 2006 Sep 15;16(18):4839-41. Epub 2006 Jun 30.Synthesis and receptor binding properties of chimeric peptides containing a mu-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac-RYYRIK-amide.
Ref 528785Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 534460J Med Chem. 1997 Aug 29;40(18):2948-52.Synthesis and pharmacological activity of deltorphin and dermorphin-related glycopeptides.
Ref 530529J Med Chem. 2010 Jan 14;53(1):402-18.Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors.
Ref 528785Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
Ref 528996Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52. Epub 2007 Aug 11.Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 528785Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
Ref 528785Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
Ref 528785Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
Ref 528785Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
Ref 528785Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 528785Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
Ref 529238Bioorg Med Chem. 2008 Mar 15;16(6):3218-23. Epub 2007 Dec 31.Novel coumarin glycoside and phenethyl vanillate from Notopterygium forbesii and their binding affinities for opioid and dopamine receptors.
Ref 528093J Med Chem. 1991 Oct;34(10):3125-32.Conformational restriction of the phenylalanine residue in a cyclic opioid peptide analogue: effects on receptor selectivity and stereospecificity.
Ref 528621J Med Chem. 2007 Jan 25;50(2):328-33.Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists.
Ref 528621J Med Chem. 2007 Jan 25;50(2):328-33.Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists.
Ref 529401J Med Chem. 2008 Apr 24;51(8):2421-31. Epub 2008 Apr 2.Herkinorin analogues with differential beta-arrestin-2 interactions.
Ref 529991J Med Chem. 2009 Mar 26;52(6):1553-7.14 beta-O-cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity.
Ref 529306J Med Chem. 2008 Mar 13;51(5):1369-76. Epub 2008 Feb 12.A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists.
Ref 529630J Med Chem. 2008 Aug 28;51(16):5109-17. Epub 2008 Aug 5.Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic.
Ref 529202J Med Chem. 2008 Jan 10;51(1):173-7. Epub 2007 Dec 7.Endomorphin-2 with a beta-turn backbone constraint retains the potent micro-opioid receptor agonist properties.
Ref 527332J Med Chem. 2004 Dec 16;47(26):6541-6.Highly selective fluorescent analogue of the potent delta-opioid receptor antagonist Dmt-Tic.
Ref 528411J Med Chem. 2006 Sep 7;49(18):5610-7.Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore.
Ref 533571J Med Chem. 1982 Dec;25(12):1423-7.Synthesis and biological evaluation of a metazocine-containing enkephalinamide. Evidence for nonidentical roles of the tyramine moiety in opiates and opioid peptides.
Ref 528594Bioorg Med Chem. 2007 Feb 15;15(4):1694-702. Epub 2006 Dec 12.Endomorphin-1 analogs with enhanced metabolic stability and systemic analgesic activity: design, synthesis, and pharmacological characterization.
Ref 529246Bioorg Med Chem. 2008 Mar 15;16(6):3032-8. Epub 2007 Dec 23.Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502).
Ref 529088J Med Chem. 2007 Nov 1;50(22):5528-32. Epub 2007 Oct 10.Development of novel enkephalin analogues that have enhanced opioid activities at both mu and delta opioid receptors.
Ref 529395J Med Chem. 2008 Apr 24;51(8):2571-4. Epub 2008 Mar 28.Blood-brain barrier penetration by two dermorphin tetrapeptide analogues: role of lipophilicity vs structural flexibility.
Ref 531505J Med Chem. 1990 Aug;33(8):2286-96.Electrophilic alpha-methylene-gamma-lactone and isothiocyanate opioid ligands related to etorphine.
Ref 529246Bioorg Med Chem. 2008 Mar 15;16(6):3032-8. Epub 2007 Dec 23.Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502).
Ref 528832J Med Chem. 2007 Jun 14;50(12):2753-66. Epub 2007 May 12.Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mixed mu-agonist/delta-antagonist and dual mu-agonist/delta-agonist opioid ligands.
Ref 529630J Med Chem. 2008 Aug 28;51(16):5109-17. Epub 2008 Aug 5.Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic.
Ref 529630J Med Chem. 2008 Aug 28;51(16):5109-17. Epub 2008 Aug 5.Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic.
Ref 528655Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. Epub 2007 Jan 17.High-affinity carbamate analogues of morphinan at opioid receptors.
Ref 529704J Med Chem. 2008 Sep 25;51(18):5866-70.Novel opioid peptide derived antagonists containing (2S)-2-methyl-3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid [(2S)-Mdcp].
Ref 528655Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. Epub 2007 Jan 17.High-affinity carbamate analogues of morphinan at opioid receptors.
Ref 528655Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. Epub 2007 Jan 17.High-affinity carbamate analogues of morphinan at opioid receptors.
Ref 528655Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. Epub 2007 Jan 17.High-affinity carbamate analogues of morphinan at opioid receptors.
Ref 531038Bioorg Med Chem. 2010 Aug 15;18(16):6024-30. Epub 2010 Jun 25.Role of 2',6'-dimethyl-l-tyrosine (Dmt) in some opioid lead compounds.
Ref 528655Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. Epub 2007 Jan 17.High-affinity carbamate analogues of morphinan at opioid receptors.
Ref 528787Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. Epub 2007 Mar 30.In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors.
Ref 528787Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. Epub 2007 Mar 30.In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors.
Ref 528787Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. Epub 2007 Mar 30.In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors.
Ref 528787Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. Epub 2007 Mar 30.In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors.
Ref 528411J Med Chem. 2006 Sep 7;49(18):5610-7.Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore.
Ref 529816Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8. Epub 2008 Nov 7.Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
Ref 533376J Med Chem. 1986 Nov;29(11):2370-5.Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors.
Ref 530447J Med Chem. 2009 Nov 12;52(21):6941-5.Agonist vs antagonist behavior of delta opioid peptides containing novel phenylalanine analogues in place of Tyr(1).
Ref 528269J Med Chem. 2006 Jun 29;49(13):3990-3.New 2',6'-dimethyl-L-tyrosine (Dmt) opioid peptidomimetics based on the Aba-Gly scaffold. Development of unique mu-opioid receptor ligands.
Ref 531109Bioorg Med Chem Lett. 2010 Sep 15;20(18):5405-10. Epub 2010 Aug 3.SAR development of a series of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as kappa opioid receptor antagonists. Part 2.
Ref 551379Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. Epub 2006 Jun 13.
Ref 528832J Med Chem. 2007 Jun 14;50(12):2753-66. Epub 2007 May 12.Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mixed mu-agonist/delta-antagonist and dual mu-agonist/delta-agonist opioid ligands.
Ref 529630J Med Chem. 2008 Aug 28;51(16):5109-17. Epub 2008 Aug 5.Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic.
Ref 529630J Med Chem. 2008 Aug 28;51(16):5109-17. Epub 2008 Aug 5.Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic.
Ref 528832J Med Chem. 2007 Jun 14;50(12):2753-66. Epub 2007 May 12.Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mixed mu-agonist/delta-antagonist and dual mu-agonist/delta-agonist opioid ligands.
Ref 528621J Med Chem. 2007 Jan 25;50(2):328-33.Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists.
Ref 529480Bioorg Med Chem. 2008 Jun 15;16(12):6415-22. Epub 2008 May 3.Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling.
Ref 529816Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8. Epub 2008 Nov 7.Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
Ref 529246Bioorg Med Chem. 2008 Mar 15;16(6):3032-8. Epub 2007 Dec 23.Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502).
Ref 529630J Med Chem. 2008 Aug 28;51(16):5109-17. Epub 2008 Aug 5.Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic.
Ref 534004J Med Chem. 1993 Mar 19;36(6):708-19.A topochemical approach to explain morphiceptin bioactivity.
Ref 530013Bioorg Med Chem Lett. 2009 Apr 15;19(8):2289-94. Epub 2009 Feb 25.Syntheses of novel high affinity ligands for opioid receptors.
Ref 528376J Med Chem. 2006 Aug 24;49(17):5382-5.Replacement of the N-terminal tyrosine residue in opioid peptides with 3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid (Dcp) results in novel opioid antagonists.
Ref 528411J Med Chem. 2006 Sep 7;49(18):5610-7.Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore.
Ref 528412J Med Chem. 2006 Sep 7;49(18):5640-3.New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores.
Ref 529202J Med Chem. 2008 Jan 10;51(1):173-7. Epub 2007 Dec 7.Endomorphin-2 with a beta-turn backbone constraint retains the potent micro-opioid receptor agonist properties.
Ref 534004J Med Chem. 1993 Mar 19;36(6):708-19.A topochemical approach to explain morphiceptin bioactivity.
Ref 528646J Med Chem. 2007 Feb 8;50(3):512-20.Synthesis and characterization of potent and selective mu-opioid receptor antagonists, [Dmt(1), D-2-Nal(4)]endomorphin-1 (Antanal-1) and [Dmt(1), D-2-Nal(4)]endomorphin-2 (Antanal-2).
Ref 528190Bioorg Med Chem Lett. 2006 Jul 15;16(14):3688-92. Epub 2006 May 8.Opioid receptor binding and antinociceptive activity of the analogues of endomorphin-2 and morphiceptin with phenylalanine mimics inthe position 3 or 4.
Ref 529480Bioorg Med Chem. 2008 Jun 15;16(12):6415-22. Epub 2008 May 3.Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling.
Ref 528724Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. Epub 2007 Feb 2.Further studies of tyrosine surrogates in opioid receptor peptide ligands.
Ref 528724Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. Epub 2007 Feb 2.Further studies of tyrosine surrogates in opioid receptor peptide ligands.
Ref 528724Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. Epub 2007 Feb 2.Further studies of tyrosine surrogates in opioid receptor peptide ligands.
Ref 528724Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. Epub 2007 Feb 2.Further studies of tyrosine surrogates in opioid receptor peptide ligands.
Ref 528411J Med Chem. 2006 Sep 7;49(18):5610-7.Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore.
Ref 530160Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. Epub 2009 May 3.Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208.
Ref 527332J Med Chem. 2004 Dec 16;47(26):6541-6.Highly selective fluorescent analogue of the potent delta-opioid receptor antagonist Dmt-Tic.
Ref 530160Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. Epub 2009 May 3.Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208.
Ref 534004J Med Chem. 1993 Mar 19;36(6):708-19.A topochemical approach to explain morphiceptin bioactivity.
Ref 527758Bioorg Med Chem Lett. 2005 Dec 15;15(24):5517-20. Epub 2005 Sep 23.New series of potent delta-opioid antagonists containing the H-Dmt-Tic-NH-hexyl-NH-R motif.
Ref 528724Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. Epub 2007 Feb 2.Further studies of tyrosine surrogates in opioid receptor peptide ligands.
Ref 534004J Med Chem. 1993 Mar 19;36(6):708-19.A topochemical approach to explain morphiceptin bioactivity.
Ref 527916J Med Chem. 2005 Dec 15;48(25):8035-44.Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists.
Ref 528724Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. Epub 2007 Feb 2.Further studies of tyrosine surrogates in opioid receptor peptide ligands.
Ref 528238J Med Chem. 2006 Jun 15;49(12):3653-8.6-N,N-dimethylamino-2,3-naphthalimide: a new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides.
Ref 529202J Med Chem. 2008 Jan 10;51(1):173-7. Epub 2007 Dec 7.Endomorphin-2 with a beta-turn backbone constraint retains the potent micro-opioid receptor agonist properties.
Ref 527916J Med Chem. 2005 Dec 15;48(25):8035-44.Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists.
Ref 528411J Med Chem. 2006 Sep 7;49(18):5610-7.Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore.
Ref 530447J Med Chem. 2009 Nov 12;52(21):6941-5.Agonist vs antagonist behavior of delta opioid peptides containing novel phenylalanine analogues in place of Tyr(1).
Ref 530013Bioorg Med Chem Lett. 2009 Apr 15;19(8):2289-94. Epub 2009 Feb 25.Syntheses of novel high affinity ligands for opioid receptors.
Ref 528411J Med Chem. 2006 Sep 7;49(18):5610-7.Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore.
Ref 528193J Med Chem. 2006 May 18;49(10):2868-75.Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors.
Ref 528411J Med Chem. 2006 Sep 7;49(18):5610-7.Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 528193J Med Chem. 2006 May 18;49(10):2868-75.Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors.
Ref 528621J Med Chem. 2007 Jan 25;50(2):328-33.Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists.
Ref 528621J Med Chem. 2007 Jan 25;50(2):328-33.Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists.
Ref 528193J Med Chem. 2006 May 18;49(10):2868-75.Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 528621J Med Chem. 2007 Jan 25;50(2):328-33.Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists.
Ref 528621J Med Chem. 2007 Jan 25;50(2):328-33.Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists.
Ref 528621J Med Chem. 2007 Jan 25;50(2):328-33.Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists.
Ref 529306J Med Chem. 2008 Mar 13;51(5):1369-76. Epub 2008 Feb 12.A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists.
Ref 529630J Med Chem. 2008 Aug 28;51(16):5109-17. Epub 2008 Aug 5.Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 528594Bioorg Med Chem. 2007 Feb 15;15(4):1694-702. Epub 2006 Dec 12.Endomorphin-1 analogs with enhanced metabolic stability and systemic analgesic activity: design, synthesis, and pharmacological characterization.
Ref 529306J Med Chem. 2008 Mar 13;51(5):1369-76. Epub 2008 Feb 12.A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists.
Ref 528785Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 528692J Med Chem. 2007 Mar 22;50(6):1414-7. Epub 2007 Feb 22.Dicarba analogues of the cyclic enkephalin peptides H-Tyr-c[D-Cys-Gly-Phe-D(or L)-Cys]NH(2) retain high opioid activity.
Ref 530529J Med Chem. 2010 Jan 14;53(1):402-18.Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors.
Ref 528785Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
Ref 528875J Med Chem. 2007 Jun 28;50(13):3138-42. Epub 2007 Jun 1.Synthesis of stable and potent delta/mu opioid peptides: analogues of H-Tyr-c[D-Cys-Gly-Phe-D-Cys]-OH by ring-closing metathesis.
Ref 530707Bioorg Med Chem Lett. 2010 Mar 1;20(5):1507-9. Epub 2010 Jan 25.Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors.
Ref 528193J Med Chem. 2006 May 18;49(10):2868-75.Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors.
Ref 528193J Med Chem. 2006 May 18;49(10):2868-75.Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors.
Ref 528193J Med Chem. 2006 May 18;49(10):2868-75.Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors.
Ref 528193J Med Chem. 2006 May 18;49(10):2868-75.Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors.
Ref 528193J Med Chem. 2006 May 18;49(10):2868-75.Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors.
Ref 528193J Med Chem. 2006 May 18;49(10):2868-75.Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors.
Ref 528193J Med Chem. 2006 May 18;49(10):2868-75.Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors.
Ref 528058J Med Chem. 2006 Mar 9;49(5):1773-80.Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists.
Ref 528058J Med Chem. 2006 Mar 9;49(5):1773-80.Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists.
Ref 530160Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. Epub 2009 May 3.Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 530052Bioorg Med Chem Lett. 2009 May 1;19(9):2519-23. Epub 2009 Mar 14.The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 530529J Med Chem. 2010 Jan 14;53(1):402-18.Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors.
Ref 528785Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
Ref 528692J Med Chem. 2007 Mar 22;50(6):1414-7. Epub 2007 Feb 22.Dicarba analogues of the cyclic enkephalin peptides H-Tyr-c[D-Cys-Gly-Phe-D(or L)-Cys]NH(2) retain high opioid activity.
Ref 530529J Med Chem. 2010 Jan 14;53(1):402-18.Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors.
Ref 528692J Med Chem. 2007 Mar 22;50(6):1414-7. Epub 2007 Feb 22.Dicarba analogues of the cyclic enkephalin peptides H-Tyr-c[D-Cys-Gly-Phe-D(or L)-Cys]NH(2) retain high opioid activity.
Ref 528875J Med Chem. 2007 Jun 28;50(13):3138-42. Epub 2007 Jun 1.Synthesis of stable and potent delta/mu opioid peptides: analogues of H-Tyr-c[D-Cys-Gly-Phe-D-Cys]-OH by ring-closing metathesis.
Ref 528787Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. Epub 2007 Mar 30.In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 528996Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52. Epub 2007 Aug 11.Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 529132Bioorg Med Chem Lett. 2007 Dec 15;17(24):6841-6. Epub 2007 Oct 17.Structure activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 2.
Ref 530529J Med Chem. 2010 Jan 14;53(1):402-18.Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors.
Ref 551379Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. Epub 2006 Jun 13.
Ref 529724J Med Chem. 2008 Oct 23;51(20):6334-47. Epub 2008 Sep 27.The importance of micelle-bound states for the bioactivities of bifunctional peptide derivatives for delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists.
Ref 530160Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. Epub 2009 May 3.Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208.
Ref 530160Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. Epub 2009 May 3.Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208.
Ref 527490Bioorg Med Chem Lett. 2005 Apr 1;15(7):1847-50.Structure-activity relationship of the novel bivalent and C-terminal modified analogues of endomorphin-2.
Ref 528093J Med Chem. 1991 Oct;34(10):3125-32.Conformational restriction of the phenylalanine residue in a cyclic opioid peptide analogue: effects on receptor selectivity and stereospecificity.
Ref 528655Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. Epub 2007 Jan 17.High-affinity carbamate analogues of morphinan at opioid receptors.
Ref 529132Bioorg Med Chem Lett. 2007 Dec 15;17(24):6841-6. Epub 2007 Oct 17.Structure activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 2.
Ref 529132Bioorg Med Chem Lett. 2007 Dec 15;17(24):6841-6. Epub 2007 Oct 17.Structure activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 2.
Ref 533958J Med Chem. 1993 Nov 26;36(24):3748-56.Phe3-substituted analogues of deltorphin C. Spatial conformation and topography of the aromatic ring in peptide recognition by delta opioid receptors.
Ref 533543J Med Chem. 1982 Aug;25(8):913-9.Potential affinity labels for the opiate receptor based on fentanyl and related compounds.
Ref 531086Bioorg Med Chem Lett. 2010 Sep 1;20(17):5035-8. Epub 2010 Jul 13.Synthesis of pyrrolomorphinan derivatives as kappa opioid agonists.
Ref 528238J Med Chem. 2006 Jun 15;49(12):3653-8.6-N,N-dimethylamino-2,3-naphthalimide: a new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides.
Ref 530324J Med Chem. 2009 Sep 24;52(18):5685-702.Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) benzamide (ADL5747).
Ref 529429Bioorg Med Chem. 2008 May 15;16(10):5653-64. Epub 2008 Mar 30.Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 6: Opioid receptor binding properties of cyclic variants of 8-carboxamidocyclazocine.
Ref 530073Bioorg Med Chem Lett. 2009 May 15;19(10):2792-5. Epub 2009 Mar 26.Design and synthesis of novel delta opioid receptor agonists and their pharmacologies.
Ref 551379Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. Epub 2006 Jun 13.
Ref 530073Bioorg Med Chem Lett. 2009 May 15;19(10):2792-5. Epub 2009 Mar 26.Design and synthesis of novel delta opioid receptor agonists and their pharmacologies.
Ref 551379Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. Epub 2006 Jun 13.
Ref 551379Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. Epub 2006 Jun 13.
Ref 551379Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. Epub 2006 Jun 13.
Ref 530556Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4. Epub 2009 Nov 13.Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology.
Ref 551379Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. Epub 2006 Jun 13.
Ref 528655Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. Epub 2007 Jan 17.High-affinity carbamate analogues of morphinan at opioid receptors.
Ref 528655Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. Epub 2007 Jan 17.High-affinity carbamate analogues of morphinan at opioid receptors.
Ref 551379Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. Epub 2006 Jun 13.
Ref 528070J Med Chem. 1991 Aug;34(8):2438-44.Electrophilic gamma-lactone kappa-opioid receptor probes. Analogues of 2'-hydroxy-2-tetrahydrofurfuryl-5,9-dimethyl-6,7-benzomorphan diastereomers.
Ref 528787Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. Epub 2007 Mar 30.In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors.
Ref 530428J Med Chem. 2009 Nov 12;52(21):6814-21.The effects of C-terminal modifications on the opioid activity of [N-benzylTyr(1)]dynorphin A-(1-11) analogues.
Ref 528939J Biol Chem. 2007 Sep 14;282(37):27126-32. Epub 2007 Jul 6.Live cell monitoring of mu-opioid receptor-mediated G-protein activation reveals strong biological activity of close morphine biosynthetic precursors.
Ref 528939J Biol Chem. 2007 Sep 14;282(37):27126-32. Epub 2007 Jul 6.Live cell monitoring of mu-opioid receptor-mediated G-protein activation reveals strong biological activity of close morphine biosynthetic precursors.
Ref 528939J Biol Chem. 2007 Sep 14;282(37):27126-32. Epub 2007 Jul 6.Live cell monitoring of mu-opioid receptor-mediated G-protein activation reveals strong biological activity of close morphine biosynthetic precursors.
Ref 533377J Med Chem. 1986 Jul;29(7):1222-5.Peptides as receptor selectivity modulators of opiate pharmacophores.
Ref 530707Bioorg Med Chem Lett. 2010 Mar 1;20(5):1507-9. Epub 2010 Jan 25.Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors.
Ref 528832J Med Chem. 2007 Jun 14;50(12):2753-66. Epub 2007 May 12.Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mixed mu-agonist/delta-antagonist and dual mu-agonist/delta-agonist opioid ligands.
Ref 528832J Med Chem. 2007 Jun 14;50(12):2753-66. Epub 2007 May 12.Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mixed mu-agonist/delta-antagonist and dual mu-agonist/delta-agonist opioid ligands.
Ref 528376J Med Chem. 2006 Aug 24;49(17):5382-5.Replacement of the N-terminal tyrosine residue in opioid peptides with 3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid (Dcp) results in novel opioid antagonists.
Ref 530013Bioorg Med Chem Lett. 2009 Apr 15;19(8):2289-94. Epub 2009 Feb 25.Syntheses of novel high affinity ligands for opioid receptors.
Ref 527461Bioorg Med Chem Lett. 2005 Mar 15;15(6):1583-6.Synthesis and in vitro biological evaluation of a carbon glycoside analogue of morphine-6-glucuronide.
Ref 528724Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. Epub 2007 Feb 2.Further studies of tyrosine surrogates in opioid receptor peptide ligands.
Ref 528724Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. Epub 2007 Feb 2.Further studies of tyrosine surrogates in opioid receptor peptide ligands.
Ref 533377J Med Chem. 1986 Jul;29(7):1222-5.Peptides as receptor selectivity modulators of opiate pharmacophores.
Ref 530160Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. Epub 2009 May 3.Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208.
Ref 530160Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. Epub 2009 May 3.Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208.
Ref 529991J Med Chem. 2009 Mar 26;52(6):1553-7.14 beta-O-cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity.
Ref 528058J Med Chem. 2006 Mar 9;49(5):1773-80.Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 528606J Med Chem. 2007 Jan 11;50(1):165-8.Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 528875J Med Chem. 2007 Jun 28;50(13):3138-42. Epub 2007 Jun 1.Synthesis of stable and potent delta/mu opioid peptides: analogues of H-Tyr-c[D-Cys-Gly-Phe-D-Cys]-OH by ring-closing metathesis.
Ref 528058J Med Chem. 2006 Mar 9;49(5):1773-80.Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists.
Ref 529306J Med Chem. 2008 Mar 13;51(5):1369-76. Epub 2008 Feb 12.A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists.
Ref 528606J Med Chem. 2007 Jan 11;50(1):165-8.Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors.
Ref 528058J Med Chem. 2006 Mar 9;49(5):1773-80.Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists.
Ref 530529J Med Chem. 2010 Jan 14;53(1):402-18.Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors.
Ref 534004J Med Chem. 1993 Mar 19;36(6):708-19.A topochemical approach to explain morphiceptin bioactivity.
Ref 528238J Med Chem. 2006 Jun 15;49(12):3653-8.6-N,N-dimethylamino-2,3-naphthalimide: a new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides.
Ref 529662Bioorg Med Chem Lett. 2008 Sep 15;18(18):4978-81. Epub 2008 Aug 12.Synthesis of N-isobutylnoroxymorphone from naltrexone by a selective cyclopropane ring opening reaction.
Ref 528300Bioorg Med Chem Lett. 2006 Sep 15;16(18):4946-50. Epub 2006 Jul 7.Synthesis and evaluation of 3-aminopropionyl substituted fentanyl analogues for opioid activity.
Ref 534004J Med Chem. 1993 Mar 19;36(6):708-19.A topochemical approach to explain morphiceptin bioactivity.
Ref 534460J Med Chem. 1997 Aug 29;40(18):2948-52.Synthesis and pharmacological activity of deltorphin and dermorphin-related glycopeptides.
Ref 527228Bioorg Med Chem Lett. 2004 Nov 1;14(21):5275-9.Design and synthesis of 4-phenyl piperidine compounds targeting the mu receptor.
Ref 528853J Med Chem. 2007 Jun 14;50(12):2779-86. Epub 2007 May 22.Design, synthesis, and biological evaluation of novel bifunctional C-terminal-modified peptides for delta/mu opioid receptor agonists and neurokinin-1 receptor antagonists.
Ref 526156J Med Chem. 2001 Oct 11;44(21):3391-401.From hit to lead. Analyzing structure-profile relationships.
Ref 531023J Med Chem. 2010 Aug 12;53(15):5491-501.Biological and conformational evaluation of bifunctional compounds for opioid receptor agonists and neurokinin 1 receptor antagonists possessing two penicillamines.
Ref 530077Bioorg Med Chem Lett. 2009 May 15;19(10):2811-4. Epub 2009 Mar 26.Design, synthesis, and characterization of 6beta-naltrexol analogs, and their selectivity for in vitro opioid receptor subtypes.
Ref 527693J Med Chem. 2005 Aug 25;48(17):5608-11.From the potent and selective mu opioid receptor agonist H-Dmt-d-Arg-Phe-Lys-NH(2) to the potent delta antagonist H-Dmt-Tic-Phe-Lys(Z)-OH.
Ref 533958J Med Chem. 1993 Nov 26;36(24):3748-56.Phe3-substituted analogues of deltorphin C. Spatial conformation and topography of the aromatic ring in peptide recognition by delta opioid receptors.
Ref 529704J Med Chem. 2008 Sep 25;51(18):5866-70.Novel opioid peptide derived antagonists containing (2S)-2-methyl-3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid [(2S)-Mdcp].
Ref 528058J Med Chem. 2006 Mar 9;49(5):1773-80.Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists.
Ref 551379Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. Epub 2006 Jun 13.
Ref 551379Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. Epub 2006 Jun 13.
Ref 551379Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. Epub 2006 Jun 13.
Ref 530073Bioorg Med Chem Lett. 2009 May 15;19(10):2792-5. Epub 2009 Mar 26.Design and synthesis of novel delta opioid receptor agonists and their pharmacologies.
Ref 551379Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. Epub 2006 Jun 13.
Ref 551379Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. Epub 2006 Jun 13.
Ref 528787Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. Epub 2007 Mar 30.In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors.
Ref 528655Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. Epub 2007 Jan 17.High-affinity carbamate analogues of morphinan at opioid receptors.
Ref 528655Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. Epub 2007 Jan 17.High-affinity carbamate analogues of morphinan at opioid receptors.
Ref 528787Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. Epub 2007 Mar 30.In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors.
Ref 551379Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. Epub 2006 Jun 13.
Ref 530556Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4. Epub 2009 Nov 13.Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology.
Ref 533539J Med Chem. 1981 Jul;24(7):903-6.Synthesis of analogues of acetylmethadol and methadol as potential narcotic antagonists.
Ref 533539J Med Chem. 1981 Jul;24(7):903-6.Synthesis of analogues of acetylmethadol and methadol as potential narcotic antagonists.
Ref 530556Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4. Epub 2009 Nov 13.Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology.
Ref 528787Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. Epub 2007 Mar 30.In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors.
Ref 528787Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. Epub 2007 Mar 30.In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors.
Ref 531038Bioorg Med Chem. 2010 Aug 15;18(16):6024-30. Epub 2010 Jun 25.Role of 2',6'-dimethyl-l-tyrosine (Dmt) in some opioid lead compounds.
Ref 529365Bioorg Med Chem. 2008 Apr 15;16(8):4341-6. Epub 2008 Mar 4.Internalisation of the mu-opioid receptor by endomorphin-1 and leu-enkephalin is dependant on aromatic amino acid residues.
Ref 529365Bioorg Med Chem. 2008 Apr 15;16(8):4341-6. Epub 2008 Mar 4.Internalisation of the mu-opioid receptor by endomorphin-1 and leu-enkephalin is dependant on aromatic amino acid residues.
Ref 528939J Biol Chem. 2007 Sep 14;282(37):27126-32. Epub 2007 Jul 6.Live cell monitoring of mu-opioid receptor-mediated G-protein activation reveals strong biological activity of close morphine biosynthetic precursors.
Ref 529365Bioorg Med Chem. 2008 Apr 15;16(8):4341-6. Epub 2008 Mar 4.Internalisation of the mu-opioid receptor by endomorphin-1 and leu-enkephalin is dependant on aromatic amino acid residues.
Ref 529401J Med Chem. 2008 Apr 24;51(8):2421-31. Epub 2008 Apr 2.Herkinorin analogues with differential beta-arrestin-2 interactions.
Ref 529365Bioorg Med Chem. 2008 Apr 15;16(8):4341-6. Epub 2008 Mar 4.Internalisation of the mu-opioid receptor by endomorphin-1 and leu-enkephalin is dependant on aromatic amino acid residues.
Ref 527951J Med Chem. 2006 Jan 12;49(1):256-62.Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors.
Ref 534460J Med Chem. 1997 Aug 29;40(18):2948-52.Synthesis and pharmacological activity of deltorphin and dermorphin-related glycopeptides.
Ref 530314Bioorg Med Chem Lett. 2009 Sep 15;19(18):5387-91. Epub 2009 Jul 30.Molecular modeling studies to predict the possible binding modes of endomorphin analogs in mu opioid receptor.
Ref 528832J Med Chem. 2007 Jun 14;50(12):2753-66. Epub 2007 May 12.Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mixed mu-agonist/delta-antagonist and dual mu-agonist/delta-agonist opioid ligands.
Ref 528832J Med Chem. 2007 Jun 14;50(12):2753-66. Epub 2007 May 12.Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mixed mu-agonist/delta-antagonist and dual mu-agonist/delta-agonist opioid ligands.
Ref 528190Bioorg Med Chem Lett. 2006 Jul 15;16(14):3688-92. Epub 2006 May 8.Opioid receptor binding and antinociceptive activity of the analogues of endomorphin-2 and morphiceptin with phenylalanine mimics inthe position 3 or 4.
Ref 528832J Med Chem. 2007 Jun 14;50(12):2753-66. Epub 2007 May 12.Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mixed mu-agonist/delta-antagonist and dual mu-agonist/delta-agonist opioid ligands.
Ref 528832J Med Chem. 2007 Jun 14;50(12):2753-66. Epub 2007 May 12.Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mixed mu-agonist/delta-antagonist and dual mu-agonist/delta-agonist opioid ligands.
Ref 528190Bioorg Med Chem Lett. 2006 Jul 15;16(14):3688-92. Epub 2006 May 8.Opioid receptor binding and antinociceptive activity of the analogues of endomorphin-2 and morphiceptin with phenylalanine mimics inthe position 3 or 4.
Ref 528269J Med Chem. 2006 Jun 29;49(13):3990-3.New 2',6'-dimethyl-L-tyrosine (Dmt) opioid peptidomimetics based on the Aba-Gly scaffold. Development of unique mu-opioid receptor ligands.
Ref 528190Bioorg Med Chem Lett. 2006 Jul 15;16(14):3688-92. Epub 2006 May 8.Opioid receptor binding and antinociceptive activity of the analogues of endomorphin-2 and morphiceptin with phenylalanine mimics inthe position 3 or 4.
Ref 528832J Med Chem. 2007 Jun 14;50(12):2753-66. Epub 2007 May 12.Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mixed mu-agonist/delta-antagonist and dual mu-agonist/delta-agonist opioid ligands.
Ref 528190Bioorg Med Chem Lett. 2006 Jul 15;16(14):3688-92. Epub 2006 May 8.Opioid receptor binding and antinociceptive activity of the analogues of endomorphin-2 and morphiceptin with phenylalanine mimics inthe position 3 or 4.
Ref 528832J Med Chem. 2007 Jun 14;50(12):2753-66. Epub 2007 May 12.Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mixed mu-agonist/delta-antagonist and dual mu-agonist/delta-agonist opioid ligands.
Ref 530314Bioorg Med Chem Lett. 2009 Sep 15;19(18):5387-91. Epub 2009 Jul 30.Molecular modeling studies to predict the possible binding modes of endomorphin analogs in mu opioid receptor.
Ref 529816Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8. Epub 2008 Nov 7.Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
Ref 529630J Med Chem. 2008 Aug 28;51(16):5109-17. Epub 2008 Aug 5.Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic.
Ref 529480Bioorg Med Chem. 2008 Jun 15;16(12):6415-22. Epub 2008 May 3.Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling.
Ref 530314Bioorg Med Chem Lett. 2009 Sep 15;19(18):5387-91. Epub 2009 Jul 30.Molecular modeling studies to predict the possible binding modes of endomorphin analogs in mu opioid receptor.
Ref 529246Bioorg Med Chem. 2008 Mar 15;16(6):3032-8. Epub 2007 Dec 23.Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502).
Ref 529246Bioorg Med Chem. 2008 Mar 15;16(6):3032-8. Epub 2007 Dec 23.Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502).
Ref 529630J Med Chem. 2008 Aug 28;51(16):5109-17. Epub 2008 Aug 5.Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic.
Ref 529480Bioorg Med Chem. 2008 Jun 15;16(12):6415-22. Epub 2008 May 3.Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling.
Ref 529816Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8. Epub 2008 Nov 7.Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
Ref 529480Bioorg Med Chem. 2008 Jun 15;16(12):6415-22. Epub 2008 May 3.Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling.
Ref 528190Bioorg Med Chem Lett. 2006 Jul 15;16(14):3688-92. Epub 2006 May 8.Opioid receptor binding and antinociceptive activity of the analogues of endomorphin-2 and morphiceptin with phenylalanine mimics inthe position 3 or 4.
Ref 529246Bioorg Med Chem. 2008 Mar 15;16(6):3032-8. Epub 2007 Dec 23.Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502).
Ref 528412J Med Chem. 2006 Sep 7;49(18):5640-3.New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores.
Ref 529480Bioorg Med Chem. 2008 Jun 15;16(12):6415-22. Epub 2008 May 3.Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling.
Ref 528832J Med Chem. 2007 Jun 14;50(12):2753-66. Epub 2007 May 12.Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mixed mu-agonist/delta-antagonist and dual mu-agonist/delta-agonist opioid ligands.
Ref 528282Bioorg Med Chem Lett. 2006 Sep 15;16(18):4839-41. Epub 2006 Jun 30.Synthesis and receptor binding properties of chimeric peptides containing a mu-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac-RYYRIK-amide.
Ref 530626Bioorg Med Chem Lett. 2010 Feb 1;20(3):1055-8. Epub 2009 Dec 26.Investigation of Beckett-Casy model 1: synthesis of novel 16,17-seco-naltrexone derivatives and their pharmacology.
Ref 528411J Med Chem. 2006 Sep 7;49(18):5610-7.Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore.
Ref 530269J Med Chem. 2009 Dec 10;52(23):7372-5.Discovery of dermorphin-based affinity labels with subnanomolar affinity for mu opioid receptors.
Ref 529202J Med Chem. 2008 Jan 10;51(1):173-7. Epub 2007 Dec 7.Endomorphin-2 with a beta-turn backbone constraint retains the potent micro-opioid receptor agonist properties.
Ref 528269J Med Chem. 2006 Jun 29;49(13):3990-3.New 2',6'-dimethyl-L-tyrosine (Dmt) opioid peptidomimetics based on the Aba-Gly scaffold. Development of unique mu-opioid receptor ligands.
Ref 528411J Med Chem. 2006 Sep 7;49(18):5610-7.Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore.
Ref 534004J Med Chem. 1993 Mar 19;36(6):708-19.A topochemical approach to explain morphiceptin bioactivity.
Ref 528724Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. Epub 2007 Feb 2.Further studies of tyrosine surrogates in opioid receptor peptide ligands.
Ref 529630J Med Chem. 2008 Aug 28;51(16):5109-17. Epub 2008 Aug 5.Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic.
Ref 528724Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. Epub 2007 Feb 2.Further studies of tyrosine surrogates in opioid receptor peptide ligands.
Ref 528724Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. Epub 2007 Feb 2.Further studies of tyrosine surrogates in opioid receptor peptide ligands.
Ref 529480Bioorg Med Chem. 2008 Jun 15;16(12):6415-22. Epub 2008 May 3.Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling.
Ref 529041Bioorg Med Chem. 2007 Nov 15;15(22):6876-81. Epub 2007 Aug 29.A new opioid designed multiple ligand derived from the micro opioid agonist endomorphin-2 and the delta opioid antagonist pharmacophore Dmt-Tic.
Ref 533377J Med Chem. 1986 Jul;29(7):1222-5.Peptides as receptor selectivity modulators of opiate pharmacophores.
Ref 528724Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. Epub 2007 Feb 2.Further studies of tyrosine surrogates in opioid receptor peptide ligands.
Ref 530160Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. Epub 2009 May 3.Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208.
Ref 527490Bioorg Med Chem Lett. 2005 Apr 1;15(7):1847-50.Structure-activity relationship of the novel bivalent and C-terminal modified analogues of endomorphin-2.
Ref 530160Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. Epub 2009 May 3.Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208.
Ref 528238J Med Chem. 2006 Jun 15;49(12):3653-8.6-N,N-dimethylamino-2,3-naphthalimide: a new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides.
Ref 527758Bioorg Med Chem Lett. 2005 Dec 15;15(24):5517-20. Epub 2005 Sep 23.New series of potent delta-opioid antagonists containing the H-Dmt-Tic-NH-hexyl-NH-R motif.
Ref 534004J Med Chem. 1993 Mar 19;36(6):708-19.A topochemical approach to explain morphiceptin bioactivity.
Ref 528724Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. Epub 2007 Feb 2.Further studies of tyrosine surrogates in opioid receptor peptide ligands.
Ref 527916J Med Chem. 2005 Dec 15;48(25):8035-44.Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists.
Ref 528724Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. Epub 2007 Feb 2.Further studies of tyrosine surrogates in opioid receptor peptide ligands.
Ref 530160Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. Epub 2009 May 3.Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208.
Ref 528411J Med Chem. 2006 Sep 7;49(18):5610-7.Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore.
Ref 528193J Med Chem. 2006 May 18;49(10):2868-75.Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors.
Ref 528785Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
Ref 528193J Med Chem. 2006 May 18;49(10):2868-75.Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors.
Ref 528621J Med Chem. 2007 Jan 25;50(2):328-33.Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists.
Ref 528376J Med Chem. 2006 Aug 24;49(17):5382-5.Replacement of the N-terminal tyrosine residue in opioid peptides with 3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid (Dcp) results in novel opioid antagonists.
Ref 528193J Med Chem. 2006 May 18;49(10):2868-75.Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors.
Ref 530314Bioorg Med Chem Lett. 2009 Sep 15;19(18):5387-91. Epub 2009 Jul 30.Molecular modeling studies to predict the possible binding modes of endomorphin analogs in mu opioid receptor.
Ref 528193J Med Chem. 2006 May 18;49(10):2868-75.Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 527916J Med Chem. 2005 Dec 15;48(25):8035-44.Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists.
Ref 529630J Med Chem. 2008 Aug 28;51(16):5109-17. Epub 2008 Aug 5.Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 528785Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 533376J Med Chem. 1986 Nov;29(11):2370-5.Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors.
Ref 527916J Med Chem. 2005 Dec 15;48(25):8035-44.Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists.
Ref 528781Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
Ref 527916J Med Chem. 2005 Dec 15;48(25):8035-44.Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists.
Ref 525699J Med Chem. 2000 Feb 24;43(4):569-80.Opiate aromatic pharmacophore structure-activity relationships in CTAP analogues determined by topographical bias, two-dimensional NMR, and biological activity assays.
Ref 529132Bioorg Med Chem Lett. 2007 Dec 15;17(24):6841-6. Epub 2007 Oct 17.Structure activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 2.
Ref 529264Bioorg Med Chem Lett. 2008 Feb 15;18(4):1350-3. Epub 2008 Jan 8.Novel highly potent mu-opioid receptor antagonist based on endomorphin-2 structure.
Ref 530558Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31. Epub 2009 Nov 20.Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine.
Ref 530461J Med Chem. 2009 Nov 12;52(21):6926-30.14beta-Arylpropiolylamino-17-cyclopropylmethyl-7,8-dihydronormorphinones and related opioids. Further examples of pseudoirreversible mu opioid receptor antagonists.
Ref 525672J Med Chem. 2000 Jan 13;43(1):114-22.Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine dependence.
Ref 525682J Med Chem. 1999 Dec 30;42(26):5359-68.Exploring the structure-activity relationships of [1-(4-tert-butyl-3'-hydroxy)benzhydryl-4-benzylpiperazine] (SL-3111), a high-affinity and selective delta-opioid receptor nonpeptide agonist ligand.
Ref 533571J Med Chem. 1982 Dec;25(12):1423-7.Synthesis and biological evaluation of a metazocine-containing enkephalinamide. Evidence for nonidentical roles of the tyramine moiety in opiates and opioid peptides.
Ref 529704J Med Chem. 2008 Sep 25;51(18):5866-70.Novel opioid peptide derived antagonists containing (2S)-2-methyl-3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid [(2S)-Mdcp].
Ref 527758Bioorg Med Chem Lett. 2005 Dec 15;15(24):5517-20. Epub 2005 Sep 23.New series of potent delta-opioid antagonists containing the H-Dmt-Tic-NH-hexyl-NH-R motif.
Ref 529414Eur J Med Chem. 2008 Nov;43(11):2307-15. Epub 2008 Feb 29.Ligand binding to nucleic acids and proteins: Does selectivity increase with strength?.
Ref 528070J Med Chem. 1991 Aug;34(8):2438-44.Electrophilic gamma-lactone kappa-opioid receptor probes. Analogues of 2'-hydroxy-2-tetrahydrofurfuryl-5,9-dimethyl-6,7-benzomorphan diastereomers.
Ref 533958J Med Chem. 1993 Nov 26;36(24):3748-56.Phe3-substituted analogues of deltorphin C. Spatial conformation and topography of the aromatic ring in peptide recognition by delta opioid receptors.
Ref 530283Bioorg Med Chem. 2009 Aug 15;17(16):5782-90. Epub 2009 Jul 18.Synthesis and characterizations of novel quinoline derivatives having mixed ligand activities at the kappa and mu receptors: Potential therapeutic efficacy against morphine dependence.
Ref 529365Bioorg Med Chem. 2008 Apr 15;16(8):4341-6. Epub 2008 Mar 4.Internalisation of the mu-opioid receptor by endomorphin-1 and leu-enkephalin is dependant on aromatic amino acid residues.
Ref 529365Bioorg Med Chem. 2008 Apr 15;16(8):4341-6. Epub 2008 Mar 4.Internalisation of the mu-opioid receptor by endomorphin-1 and leu-enkephalin is dependant on aromatic amino acid residues.
Ref 529365Bioorg Med Chem. 2008 Apr 15;16(8):4341-6. Epub 2008 Mar 4.Internalisation of the mu-opioid receptor by endomorphin-1 and leu-enkephalin is dependant on aromatic amino acid residues.
Ref 531023J Med Chem. 2010 Aug 12;53(15):5491-501.Biological and conformational evaluation of bifunctional compounds for opioid receptor agonists and neurokinin 1 receptor antagonists possessing two penicillamines.
Ref 528282Bioorg Med Chem Lett. 2006 Sep 15;16(18):4839-41. Epub 2006 Jun 30.Synthesis and receptor binding properties of chimeric peptides containing a mu-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac-RYYRIK-amide.
Ref 529816Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8. Epub 2008 Nov 7.Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
Ref 529264Bioorg Med Chem Lett. 2008 Feb 15;18(4):1350-3. Epub 2008 Jan 8.Novel highly potent mu-opioid receptor antagonist based on endomorphin-2 structure.
Ref 531165Bioorg Med Chem Lett. 2010 Nov 1;20(21):6302-5. Epub 2010 Aug 21.Design and synthesis of KNT-127, a |A-opioid receptor agonist effective by systemic administration.
Ref 528996Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52. Epub 2007 Aug 11.Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1.
Ref 531038Bioorg Med Chem. 2010 Aug 15;18(16):6024-30. Epub 2010 Jun 25.Role of 2',6'-dimethyl-l-tyrosine (Dmt) in some opioid lead compounds.
Ref 530279J Med Chem. 2009 Dec 10;52(23):7389-96.Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands.
Ref 527693J Med Chem. 2005 Aug 25;48(17):5608-11.From the potent and selective mu opioid receptor agonist H-Dmt-d-Arg-Phe-Lys-NH(2) to the potent delta antagonist H-Dmt-Tic-Phe-Lys(Z)-OH.
Ref 534460J Med Chem. 1997 Aug 29;40(18):2948-52.Synthesis and pharmacological activity of deltorphin and dermorphin-related glycopeptides.
Ref 533971J Med Chem. 1994 Jan 7;37(1):141-5.Design of cyclic deltorphins and dermenkephalins with a disulfide bridge leads to analogues with high selectivity for delta-opioid receptors.
Ref 533971J Med Chem. 1994 Jan 7;37(1):141-5.Design of cyclic deltorphins and dermenkephalins with a disulfide bridge leads to analogues with high selectivity for delta-opioid receptors.
Ref 528151Bioorg Med Chem Lett. 2006 Jul 1;16(13):3524-8. Epub 2006 Apr 24.3-(4-Piperidinyl)indoles and 3-(4-piperidinyl)pyrrolo-[2,3-b]pyridines as ligands for the ORL-1 receptor.
Ref 528269J Med Chem. 2006 Jun 29;49(13):3990-3.New 2',6'-dimethyl-L-tyrosine (Dmt) opioid peptidomimetics based on the Aba-Gly scaffold. Development of unique mu-opioid receptor ligands.
Ref 529276J Med Chem. 2008 Feb 28;51(4):1058-62. Epub 2008 Jan 31.Synthesis and pharmacological evaluation of 1,2-dihydrospiro[isoquinoline-4(3H),4'-piperidin]-3-ones as nociceptin receptor agonists.
Ref 528594Bioorg Med Chem. 2007 Feb 15;15(4):1694-702. Epub 2006 Dec 12.Endomorphin-1 analogs with enhanced metabolic stability and systemic analgesic activity: design, synthesis, and pharmacological characterization.
Ref 530314Bioorg Med Chem Lett. 2009 Sep 15;19(18):5387-91. Epub 2009 Jul 30.Molecular modeling studies to predict the possible binding modes of endomorphin analogs in mu opioid receptor.
Ref 530268Bioorg Med Chem. 2009 Aug 15;17(16):5983-8. Epub 2009 Jul 3.Aerobic oxidation of indolomorphinan without the 4,5-epoxy bridge and subsequent rearrangement of the oxidation product to spiroindolinonyl-C-normorphinan derivative.
Ref 529509J Med Chem. 1991 May;34(5):1656-61.Synthesis and structure-activity relationships of deltorphin analogues.
Ref 527461Bioorg Med Chem Lett. 2005 Mar 15;15(6):1583-6.Synthesis and in vitro biological evaluation of a carbon glycoside analogue of morphine-6-glucuronide.
Ref 530160Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. Epub 2009 May 3.Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208.
Ref 530234Bioorg Med Chem Lett. 2009 Aug 1;19(15):4115-8. Epub 2009 Jun 6.Synthesis and evaluation of new endomorphin analogues modified at the Pro(2) residue.
Ref 528190Bioorg Med Chem Lett. 2006 Jul 15;16(14):3688-92. Epub 2006 May 8.Opioid receptor binding and antinociceptive activity of the analogues of endomorphin-2 and morphiceptin with phenylalanine mimics inthe position 3 or 4.
Ref 528070J Med Chem. 1991 Aug;34(8):2438-44.Electrophilic gamma-lactone kappa-opioid receptor probes. Analogues of 2'-hydroxy-2-tetrahydrofurfuryl-5,9-dimethyl-6,7-benzomorphan diastereomers.
Ref 533376J Med Chem. 1986 Nov;29(11):2370-5.Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors.
Ref 530705Bioorg Med Chem Lett. 2010 Mar 1;20(5):1601-3. Epub 2010 Jan 22.Synthesis and evaluation of opioid receptor-binding affinity of elaeocarpenine and its analogs.
Ref 531092Eur J Med Chem. 2010 Oct;45(10):4594-600. Epub 2010 Jul 21.Synthesis and activity of endomorphin-2 and morphiceptin analogues with proline surrogates in position 2.
Ref 528193J Med Chem. 2006 May 18;49(10):2868-75.Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors.
Ref 530269J Med Chem. 2009 Dec 10;52(23):7372-5.Discovery of dermorphin-based affinity labels with subnanomolar affinity for mu opioid receptors.
Ref 528646J Med Chem. 2007 Feb 8;50(3):512-20.Synthesis and characterization of potent and selective mu-opioid receptor antagonists, [Dmt(1), D-2-Nal(4)]endomorphin-1 (Antanal-1) and [Dmt(1), D-2-Nal(4)]endomorphin-2 (Antanal-2).
Ref 528646J Med Chem. 2007 Feb 8;50(3):512-20.Synthesis and characterization of potent and selective mu-opioid receptor antagonists, [Dmt(1), D-2-Nal(4)]endomorphin-1 (Antanal-1) and [Dmt(1), D-2-Nal(4)]endomorphin-2 (Antanal-2).
Ref 528996Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52. Epub 2007 Aug 11.Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1.
Ref 527916J Med Chem. 2005 Dec 15;48(25):8035-44.Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists.
Ref 527916J Med Chem. 2005 Dec 15;48(25):8035-44.Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists.
Ref 528190Bioorg Med Chem Lett. 2006 Jul 15;16(14):3688-92. Epub 2006 May 8.Opioid receptor binding and antinociceptive activity of the analogues of endomorphin-2 and morphiceptin with phenylalanine mimics inthe position 3 or 4.
Ref 530314Bioorg Med Chem Lett. 2009 Sep 15;19(18):5387-91. Epub 2009 Jul 30.Molecular modeling studies to predict the possible binding modes of endomorphin analogs in mu opioid receptor.
Ref 527490Bioorg Med Chem Lett. 2005 Apr 1;15(7):1847-50.Structure-activity relationship of the novel bivalent and C-terminal modified analogues of endomorphin-2.
Ref 526733J Med Chem. 1992 May 1;35(9):1521-5.Phenylmorphans and analogues: opioid receptor subtype selectivity and effect of conformation on activity.
Ref 527092J Med Chem. 2004 Jun 3;47(12):3242-7.Synthesis and biological evaluation of 14-alkoxymorphinans. 21. Novel 4-alkoxy and 14-phenylpropoxy derivatives of the mu opioid receptor antagonist cyprodime.
Ref 526656J Med Chem. 2003 Jul 3;46(14):3127-37.Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.
Ref 553157Opiate-like analgesic activity in general anaesthetics. Br J Pharmacol. 1981 Jun;73(2):435-42.
Ref 530428J Med Chem. 2009 Nov 12;52(21):6814-21.The effects of C-terminal modifications on the opioid activity of [N-benzylTyr(1)]dynorphin A-(1-11) analogues.
Ref 528375J Med Chem. 2006 Aug 24;49(17):5333-8.Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorphinones and codeinones.
Ref 529816Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8. Epub 2008 Nov 7.Syntheses and opioid receptor binding properties of carboxamido-substituted opioids.
Ref 529041Bioorg Med Chem. 2007 Nov 15;15(22):6876-81. Epub 2007 Aug 29.A new opioid designed multiple ligand derived from the micro opioid agonist endomorphin-2 and the delta opioid antagonist pharmacophore Dmt-Tic.
Ref 552429Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice. Neuropsychopharmacology. 2004 Sep;29(9):1656-63.
Ref 529306J Med Chem. 2008 Mar 13;51(5):1369-76. Epub 2008 Feb 12.A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists.
Ref 531079J Med Chem. 2010 Sep 9;53(17):6386-97.Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential.
Ref 526710J Med Chem. 2003 Sep 11;46(19):4002-8.Effects of the substitution of Phe4 in the opioid peptide [D-Ala8]dynorphin A-(1-11)NH2.
Ref 527951J Med Chem. 2006 Jan 12;49(1):256-62.Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors.
Ref 527951J Med Chem. 2006 Jan 12;49(1):256-62.Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors.
Ref 528606J Med Chem. 2007 Jan 11;50(1):165-8.Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors.
Ref 530780J Med Chem. 2010 Apr 8;53(7):2875-81."Carba"-analogues of fentanyl are opioid receptor agonists.
Ref 531092Eur J Med Chem. 2010 Oct;45(10):4594-600. Epub 2010 Jul 21.Synthesis and activity of endomorphin-2 and morphiceptin analogues with proline surrogates in position 2.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.